Terguride is an ergoline derivative with mixed agonistic/antagonistic dopaminergic activity. This led to a paradoxical suggestion that it is effective in the treatment of both schizophrenia and parkinsonism. A total of 65 in- or outpatients with parkinsonism mostly of vascular or idiopathic etiology were included in a 4-week, open, multicenter trial. Terguride was administered under an increasing dose schedule which was leveled off according to the clinical response. Mostly because of nausea, vomiting, and lack of improvement 25% of inpatients and 61% of outpatients were removed from the study. The average daily dose at the end of the trial was 4.2 mg, ranging from 1.0 to 5.5 mg. The average Simpson and Angus scale total score and performance in the Spiral Drawing Task improved significantly during the trial by 20% and 38% respectively. The following adverse effects were noted most frequently throughout the study (including those who withdrew): constipation (occurred in 42% of all ratings performed during the trial) drowsiness and nausea (16% each). Adverse circulatory effects were negligible. Psychotic symptoms, including depression, confusion, hallucinations, and paranoid syndrome, each occurred in 1 patient, i.e., at a lower rate than with other dopaminergic drugs. Scotopic electroretinograms in a subsample of 7 patients showed a significant transitory decrease in the B-wave amplitude at the end of the 1st week and a subsequent return to pretreatment values.

BACKGROUND: After a stroke, patients experience sensorimotor damage, balance disorders, loss of selective movement, hypotonia and/or hypertonia, and hypersensitivity, all of which affect gait. OBJECTIVE: The aim of the study was to establish the effectiveness of Bobath therapy with additional specific soft tissue mobilizations versus standard Bobath intervention. METHODS: Subjects were randomly divided into two groups (S1 and S2) of 20 people each. Both groups underwent the same intervention (Bobath concept) over a 5-week period, while the second study group (S2) also received additional, specific soft tissue mobilization. The Berg Balance Scale (BBS), Timed Up and Go Test (TUGT), Active Range of Motion (AROM) of dorsiflexion and knee flexion and extension were used as clinical variables to assess the efficacy of therapy modalities. Data was analysed using a mixed model ANOVA. RESULTS: A significant interaction of group and time was found. The experimental (S2) group had a larger improvement of balance and AROM than the control (S1) group. There was no clear advantage of one group over the other for TUGT. CONCLUSION: The findings demonstrate that a combination of Bobath treatment and additional specific soft tissue mobilizations are more effective in increasing AROM and balance and mobility.

No abstract

No abstract

No abstract